Oramed Pharmaceuticals Stock Performance
| ORMP Stock | USD 2.33 0.06 2.64% |
Oramed Pharmaceuticals has a performance score of 2 on a scale of 0 to 100. The company holds a Beta of 1.85, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Oramed Pharmaceuticals will likely underperform. Oramed Pharmaceuticals right now holds a risk of 4.82%. Please check Oramed Pharmaceuticals maximum drawdown, and the relationship between the information ratio and expected short fall , to decide if Oramed Pharmaceuticals will be following its historical price patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Oramed Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Even with relatively unsteady primary indicators, Oramed Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in May 2024. ...more
Actual Historical Performance (%)
One Day Return 4.41 | Five Day Return (1.25) | Year To Date Return (3.27) | Ten Year Return (82.50) | All Time Return (80.25) |
Last Split Factor 1:12 | Last Split Date 2013-01-23 |
1 | Oramed Pharmaceuticals, Inc. is up 1.32 percent Thursday In Premarket Trading - InvestorsObserver | 01/25/2024 |
2 | Oramed Pharmaceuticals, Inc. has risen 6.67 percent Monday In Premarket Trading - InvestorsObserver | 02/12/2024 |
3 | Head-To-Head Contrast TransCode Therapeutics and Oramed Pharmaceuticals | 02/28/2024 |
4 | ORMP Stock Earnings Oramed Pharmaceuticals Beats EPS for Q4 2023 | 03/07/2024 |
5 | Zacks Launched the Israel 150 Platform | 03/12/2024 |
6 | Scilex clears debt, strengthens financial position | 03/19/2024 |
7 | Insider Trading | 04/01/2024 |
8 | PhaseV to Present at Upcoming Clinical Trial Events and Scientific Meetings, Highlighting the Value of Machine Learning in Drug Development | 04/08/2024 |
9 | Acquisition by Reznick Yehuda of 29800 shares of Oramed Pharmaceuticals subject to Rule 16b-3 | 04/17/2024 |
10 | Head to Head Contrast CASI Pharmaceuticals versus Oramed Pharmaceuticals - Defense World | 04/19/2024 |
| Begin Period Cash Flow | 27.5 M |
Oramed |
Oramed Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 227.00 in Oramed Pharmaceuticals on January 24, 2024 and sell it today you would earn a total of 6.00 from holding Oramed Pharmaceuticals or generate 2.64% return on investment over 90 days. Oramed Pharmaceuticals is currently generating 0.1539% in daily expected returns and assumes 4.816% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than Oramed, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Oramed Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oramed Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Oramed Pharmaceuticals, and traders can use it to determine the average amount a Oramed Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.032
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ORMP | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.82 actual daily | 42 58% of assets are more volatile |
Expected Return
| 0.15 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Oramed Pharmaceuticals is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oramed Pharmaceuticals by adding it to a well-diversified portfolio.
Oramed Pharmaceuticals Fundamentals Growth
Oramed Stock prices reflect investors' perceptions of the future prospects and financial health of Oramed Pharmaceuticals, and Oramed Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oramed Stock performance.
| Return On Equity | 0.0324 | ||||
| Return On Asset | -0.0516 | ||||
| Profit Margin | 4.12 % | ||||
| Operating Margin | (11.77) % | ||||
| Current Valuation | (19.37 M) | ||||
| Shares Outstanding | 40.52 M | ||||
| Price To Earning | (11.22) X | ||||
| Price To Book | 0.62 X | ||||
| Price To Sales | 76.20 X | ||||
| Revenue | 2.7 M | ||||
| Gross Profit | 2.7 M | ||||
| EBITDA | (36.98 M) | ||||
| Net Income | (37.76 M) | ||||
| Cash And Equivalents | 133.91 M | ||||
| Cash Per Share | 3.45 X | ||||
| Total Debt | 894 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 21.01 X | ||||
| Book Value Per Share | 4.06 X | ||||
| Cash Flow From Operations | (27.92 M) | ||||
| Earnings Per Share | 0.14 X | ||||
| Market Capitalization | 91.98 M | ||||
| Total Asset | 161.64 M | ||||
| Retained Earnings | (163.08 M) | ||||
| Working Capital | 109.37 M | ||||
| Current Asset | 31 M | ||||
| Current Liabilities | 4 M | ||||
About Oramed Pharmaceuticals Performance
To evaluate Oramed Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Oramed Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Oramed Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Oramed Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Oramed's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.00 | 0.00 | |
| Return On Tangible Assets | (0.21) | (0.22) | |
| Return On Capital Employed | (0.23) | (0.25) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.22) | (0.24) |
Things to note about Oramed Pharmaceuticals performance evaluation
Checking the ongoing alerts about Oramed Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Oramed Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oramed Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 2.7 M. Net Loss for the year was (37.76 M) with profit before overhead, payroll, taxes, and interest of 2.7 M. | |
| Oramed Pharmaceuticals currently holds about 133.91 M in cash with (27.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Oramed Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Head to Head Contrast CASI Pharmaceuticals versus Oramed Pharmaceuticals - Defense World |
- Analyzing Oramed Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oramed Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Oramed Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oramed Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oramed Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oramed Pharmaceuticals' stock. These opinions can provide insight into Oramed Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oramed Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. To learn how to invest in Oramed Stock, please use our How to Invest in Oramed Pharmaceuticals guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Oramed Stock analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |
Is Oramed Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oramed Pharmaceuticals. If investors know Oramed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oramed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.14 | Revenue Per Share 0.033 | Quarterly Revenue Growth (1.00) | Return On Assets (0.05) | Return On Equity 0.0324 |
The market value of Oramed Pharmaceuticals is measured differently than its book value, which is the value of Oramed that is recorded on the company's balance sheet. Investors also form their own opinion of Oramed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oramed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oramed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oramed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oramed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oramed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oramed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.